Celgene (NASDAQ:CELG) has been assigned a $166.00 price objective by Oppenheimer in a research report issued on Thursday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer’s price objective points to a potential upside of 53.36% from the company’s current price.

Several other equities analysts have also recently issued reports on CELG. Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective on the stock in a research report on Wednesday, August 16th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Celgene in a research report on Tuesday, August 22nd. BTIG Research reaffirmed a “neutral” rating on shares of Celgene in a research report on Tuesday, September 5th. Cowen reaffirmed a “buy” rating and issued a $150.00 price objective on shares of Celgene in a research report on Tuesday, September 12th. Finally, Bank of America reaffirmed a “buy” rating on shares of Celgene in a research report on Wednesday, September 13th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the stock. Celgene currently has a consensus rating of “Buy” and an average target price of $136.21.

Shares of Celgene (NASDAQ:CELG) traded up $0.04 on Thursday, hitting $108.24. The stock had a trading volume of 5,343,301 shares, compared to its average volume of 4,787,745. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene has a 12-month low of $94.55 and a 12-month high of $147.17. The company has a market cap of $85,849.04, a PE ratio of 17.04, a P/E/G ratio of 0.84 and a beta of 1.78.

Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same period in the previous year, the firm posted $1.58 EPS. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. sell-side analysts forecast that Celgene will post 6.67 EPS for the current fiscal year.

In related news, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.95% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Chicago Partners Investment Group LLC boosted its holdings in shares of Celgene by 756.7% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 6,631 shares of the biopharmaceutical company’s stock valued at $967,000 after purchasing an additional 5,857 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new position in shares of Celgene during the 3rd quarter valued at about $3,149,000. Public Employees Retirement System of Ohio boosted its holdings in shares of Celgene by 1.9% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 601,520 shares of the biopharmaceutical company’s stock valued at $87,714,000 after purchasing an additional 11,416 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Celgene during the 3rd quarter valued at about $1,370,000. Finally, Americafirst Capital Management LLC bought a new position in shares of Celgene in the 3rd quarter valued at about $309,000. 80.16% of the stock is owned by institutional investors and hedge funds.

WARNING: This news story was first reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/14/oppenheimer-analysts-give-celgene-celg-a-166-00-price-target.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.